Chardan Capital Has Negative Outlook of NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at Chardan Capital dropped their FY2025 EPS estimates for Intellia Therapeutics in a research note issued to investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of ($4.14) per share for the year, down from their prior forecast of ($4.02). Chardan Capital currently has a “Buy” rating and a $91.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.13) per share.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.38) earnings per share.

Several other equities analysts have also recently weighed in on NTLA. Stifel Nicolaus lowered their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Citigroup lowered their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Wedbush reiterated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday. Royal Bank of Canada restated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. Finally, William Blair reiterated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $13.86 on Thursday. The firm has a 50 day simple moving average of $18.26 and a 200 day simple moving average of $21.85. Intellia Therapeutics has a 52 week low of $12.82 and a 52 week high of $34.87. The company has a market cap of $1.41 billion, a PE ratio of -2.58 and a beta of 1.81.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds have recently bought and sold shares of NTLA. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares in the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after acquiring an additional 746,263 shares during the last quarter. State Street Corp grew its position in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Geode Capital Management LLC increased its holdings in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after purchasing an additional 49,367 shares in the last quarter. Finally, FMR LLC raised its position in Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company’s stock valued at $48,077,000 after purchasing an additional 111,104 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.